Hematologic Malignancies

University of Michigan

University of Michigan Tumor Boards

Questions discussed in this category

How would you approach therapy for a patient with symptomatic secondary CNS marginal zone lymphoma, but with low-volume systemic disease that would otherwise not warrant therapy?

Would your approach differ for a 30 year old and a 70 year old?

3 Answers available

How would you manage a CLL patient with Richters transformation that is resistant to R-CHOP with transfusion dependent cytopenias and a marrow demonstrating significant involvement by DLBCL and CLL?

2 Answers available

How would you approach therapy for BR-refractory Waldenstrom Macroglobulinemia when there is a mixed response to zanabrutinib?

1 Answer available

In light of ALK-directed therapy, what is the role of chemotherapy for patients with newly diagnosed ALK+ DLBCL?

1 Answer available

How would you approach therapy for relapsed/refractory mantle cell lymphoma restricted to the CNS?

1 Answer available

How would you manage a patient with history of follicular lymphoma treated with Bendamustine-Rituximab who now has a new FDG avid lesion that is biopsy proven CD30 positive CD20 negative DLBCL?

2 Answers available

Papers discussed in this category

Haematologica, 2021 Jun 01

Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas.

Lancet (London, England), 2019-01-19

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.

Cancer cell, 2017-06-12

Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma.

J Neurooncol, 2022 Jun 20

Chemotherapy is an efficient treatment in primary CNS MALT lymphoma.

Related Topics in Hematologic Malignancies